Project Aim(s): PD-MitoQUANT is an Innovative Medicines Initiative (IMI)Innovative Medicines Initiative (IMI) (www.imi.europa.eu) project that brings together academic experts, small and medium enterprises (SMEs), pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA)European Federation of Pharmaceutical Industries and Associations (EFPIA) (www.efpia.eu) and patient advocacy organisation Parkinson’s UKParkinson’s UK (www.p
Research
DRNI Members Research is a list of ongoing and completed research carried out by DRNI members.
You can search via project type, disease, or Principal Investigator/Researcher name.
Search
Research type
Project Aim(s): The development of neurotrophic factor therapy for Parkinson's disease (PD).
α-Synuclein (α-Syn) pathology is inextricably linked to the pathogenesis of Parkinson’s disease (PD), yet we have very limited understanding why specific neuronal populations are vulnerable to α-Syn-related PD pathology while others are much more resistant.
1. What is the Person with Parkinson's community knowledge and experience of existing voice assisted technology?
2. What is the knowledge, experience and attitudes of Speech and Language Therapists towards voice assisted technology in practice?
Parkinson’s disease is a debilitating disorder characterised by movement disorders, including tremor, cognitive dysfunction and non-motor impairments. It is the second most common age-related neurodegenerative disease with ~10 million sufferers worldwide, but the causes of tremor are poorly understood and treatment is wholly inadequate.